Sign in

John S. Weinberg

Chairman of the Board and CEO at Evercore
Board
Since February 25, 2022
Age
67 years
Education
Holds a B.A. from Princeton University (1979) and an M.B.A. from Harvard Business School (1983).
Tenure
Joined Evercore on November 1, 2016. Held leadership roles including Chairman and Executive Chairman from November 2016 until July 2020, Co-Chairman and Co-CEO from July 2020 until February 2022, and has been serving as Chairman of the Board and CEO since February 25, 2022.

Also at Evercore

JK
Jason Klurfeld
General Counsel and Corporate Secretary
TL
Tim LaLonde
Chief Financial Officer

About

John S. Weinberg has been a transformative leader at Evercore, steering the firm through significant periods of evolution with his visionary guidance and strategic decision-making.

Before his tenure at Evercore, he built a robust career at Goldman Sachs where he held senior positions such as Vice Chairman and Co-Head of Global Investment Banking, experiences that laid the foundation for his later achievements in investment banking and corporate leadership.

In addition to his executive roles, his academic background and board memberships, including contributions to Ford Motor Company, New York-Presbyterian Hospital, and the Cystic Fibrosis Foundation, underscore his broad influence both in the financial industry and in the community.

$EVR Performance Under John S. Weinberg

Past Roles

OrganizationRoleDate RangeDetails
Evercore Co-Chairman of the Board and Co-CEOJuly 2020 - Feb 25, 2022 Former position prior to his current role as Chairman and CEO
Evercore Chairman of the Board and Executive ChairmanNovember 2016 - July 2020 Held prior to his role as Co-Chairman and Co-CEO
Goldman Sachs Vice Chairman2006 - 2015 Also served as Co-Head of Global Investment Banking and Member of the Management Committee from 2002 to 2015
Goldman Sachs Associate/Partner1983 - 1992 Started as an Associate in 1983 and was promoted to Partner in 1992

External Roles

OrganizationRoleDate RangeDetails
Ford Motor Company Board Member N/A N/A
New York-Presbyterian Hospital Board Member N/A N/A
Cystic Fibrosis Foundation Board Member N/A N/A

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary $500,000 Annual Fixed annual base pay
Non-Equity Incentive Plan Compensation $6,000,000 Annual (vesting on March 1, 2023) Long-term sign-on compensation arrangement agreed in 2016

Performance Compensation

Data from  FY 2023

Bonus (Cash Distributions for Class L Interests)

DetailValue/Description
Performance Metric 2023 adjusted operating income
Maximum Distribution Cap 1.50% of 2023 adjusted operating income
Grant Date January 2023
Vesting/Conditions Immediate vesting with cancellation if employment is terminated before the distribution in Q1 2024
Additional Conditions Subject to clawback policies and compliance with restrictive covenants

RSUs for 2023 Performance

DetailValue/Description
Grant Date February 2024
Grant Date Fair Value $3,125,000
Grant Date Stock Price $176.25 (average over 10 trading days)
Number of RSUs Granted 24,559 units
Vesting Schedule Equal installments over four years; accelerated vesting upon change in control, qualifying retirement, death, or disability
Performance Metrics Holistic evaluation based on Adjusted Net Revenues, Adjusted EPS, Adjusted Net Income, Adjusted Operating Margin, and individual contributions